martes, 27 de mayo de 2014

NGC Update Service: May 26, 2014 ► U.S. Food and Drug Administration (FDA) Advisories

NGC Update Service: May 26, 2014

National Guideline Clearinghouse (NGC)

U.S. Food and Drug Administration (FDA) Advisories

  • May 15, 2014Eszopiclone Containing Sleep Aids: FDA has notified health professionals and their medical care organizations of a new warning that the insomnia drug Lunesta (eszopiclone) can cause next-day impairment of driving and other activities that require alertness. FDA recommends a decreased starting dose of Lunesta to 1 mg at bedtime. Women and men are equally susceptible to impairment from Lunesta, so the recommended starting dose of 1 mg is the same for both. FDA approved changes to the Lunesta prescribing information and the patient Medication Guide to include these new recommendations. The drug labels for generic eszopiclone products will also be updated to include these changes.
  • May 13, 2014Pradaxa (dabigatran): FDA recently completed a new study in Medicare patients comparing Pradaxa to warfarin, for risk of ischemic or clot-related stroke, bleeding in the brain, major gastrointestinal (GI) bleeding, myocardial infarction (MI), and death. This study's findings, except with regard to MI, are consistent with the clinical trial results that provided the basis for Pradaxa's approval. As a result of these latest findings, the FDA still considers Pradaxa to have a favorable benefit to risk profile and have made no changes to the current label or recommendations for use.

No hay comentarios:

Publicar un comentario